Hyper Corporation Inc. (KOSDAQ:065650)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,220.00
+390.00 (10.18%)
At close: Apr 30, 2026
Market Cap46.14B +31.8%
Revenue (ttm)76.19B +32.0%
Net Income-315.64M
EPS-114.00
Shares Out10.93M
PE Ratio116.34
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume209,747
Average Volume52,367
Open3,830.00
Previous Close3,830.00
Day's Range3,724.00 - 4,220.00
52-Week Range3,200.00 - 14,500.00
Beta1.51
RSI55.32
Earnings DateMay 13, 2026

About Hyper Corporation

Hyper Corporation Inc., a clinical stage biopharmaceutical company, focuses on the development of Alzheimer's disease (AD) and neuropathic pain treatments, and AD diagnostics. Its products under development include TRPV1 Antagonist and TRPV1 Agonist for neuropathic pain; and anti-oligomerization of beta-amyloid, receptor for advanced glycation endproduct modulator, and early diagnosis kits for AD. The company wholesales and retails electronic devices, small home appliances, TVs, routers, and PC peripherals, such as gaming monitors, mouse, and w... [Read more]

Industry Computer Programming, Data Processing, And Other Computer Related Services
Founded 1997
Employees 46
Stock Exchange KOSDAQ
Ticker Symbol 065650
Full Company Profile

Financial Performance

In 2025, Hyper Corporation's revenue was 76.19 billion, an increase of 32.04% compared to the previous year's 57.70 billion. Losses were -315.64 million, -99.61% less than in 2024.

Financial Statements